Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?
Immenschuh
Stephan
S
D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D063385:Cannabinoid Receptor Modulators / Q000502:physiology*; D004195:Disease Models, Animal; D063388:Endocannabinoids; D006801:Humans; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D017382:Reactive Oxygen Species / Q000378:metabolism; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors / Q000502:physiology; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors / Q000502:physiology; D000077285:Rimonabant; D015398:Signal Transduction / Q000502:physiology*
D000577:Amides; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D010880:Piperidines; D011720:Pyrazoles; D011725:Pyridines; D017382:Reactive Oxygen Species; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D000077285:Rimonabant; C521311:N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide